<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01558908</url>
  </required_header>
  <id_info>
    <org_study_id>MEDS-027</org_study_id>
    <nct_id>NCT01558908</nct_id>
  </id_info>
  <brief_title>Phase I/II Trial of Endometrial Regenerative Cells (ERC) in Patients With Critical Limb Ischemia</brief_title>
  <official_title>Allogeneic,Unrelated, Menstrual Derived, Mesenchymal Stem Cell-Like, Endometrial Cells; Administered Intramuscular</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medistem Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medistem Inc.</source>
  <brief_summary>
    <textblock>
      This is a 15 patient clinical trial assessing the safety and feasibility of using Endometrial&#xD;
      Regenerative Cells (ERC) in patients with critical limb ischemia (CLI) that are not eligible&#xD;
      for surgical or catheter-based interventions. Three doses of ERC will be examined. The&#xD;
      hypothesis is that ERC administration will be well-tolerated and possibly induce a&#xD;
      therapeutic benefit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the trial is to determine safety of intramuscularly derived menstrual&#xD;
      mesenchymal stem cells (otherwise known as Endometrial Regenerative Cells, or ERC) in&#xD;
      patients with critical limb ischemia ineligible for revascularization. Safety will be defined&#xD;
      as freedom from treatment associated adverse events. Efficacy parameters will comprise&#xD;
      endpoints of changes in ankle-brachial index, toe-brachial index, TcPO2, ulcer healing, rest&#xD;
      pain, quality of life, and reduction in amputation.&#xD;
&#xD;
      Patients will receive 25, 50, or 100 million menstrual derived mesenchymal stem cells&#xD;
      (Endometrial Regenerative Cells: ERC) in ten injections of 2.5, 5, or 10 million mesenchymal&#xD;
      stem cells suspended in a volume of 1 ml per injection. Injections will be spaced at least 2&#xD;
      centimeters apart from each other in the gastrocnemius muscle above the failed vascular&#xD;
      perfusion area.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>52 weeks</time_frame>
    <description>Adverse and serious events recorded</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvements post-treatment in rest pain (VAS), toe pressure and ABI, transcutaneous oximetry and ulcer status (with picture).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intramuscular injection of ERC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Administration of ERC</intervention_name>
    <description>Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.</description>
    <arm_group_label>Intramuscular injection of ERC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-pregnant patients with critical limb ischemia, Rutherford IV-V, manifested as rest&#xD;
             pain or tissue loss, or with disabling claudication, manifested as exercise induced&#xD;
             thigh or calf pain that impairs activities of daily living, who are not candidates for&#xD;
             surgical bypass or angioplasty due to unfavorable arterial anatomy or absence of&#xD;
             adequate autogenous vein for a below-knee bypass.&#xD;
&#xD;
          2. Patients over 18 years of age with an expected survival of more than one year after&#xD;
             treatment.&#xD;
&#xD;
          3. Unreconstructable arterial disease will be determined by a vascular surgeon who is not&#xD;
             participating in the study. Unreconstructable arterial disease is defined by&#xD;
             atherocclusive lesions within the arterial tree of the extremity that due to extent or&#xD;
             morphology are not amenable to surgical bypass or PTCA and stenting.&#xD;
&#xD;
          4. Patients with a maximum of 3 non-healing 'flat' surface or 'transdermal' ulcers Grades&#xD;
             1-2, no ulcer bigger than 2 centimeters (2)&#xD;
&#xD;
          5. Patients with unfavorable anatomy or who are medically unfit to undergo bypass as&#xD;
             determined by a vascular surgeon who is not participating in the study.&#xD;
&#xD;
          6. Vascular imaging (eg angiogram or MRA) to determine vascular anatomy must be conducted&#xD;
             within 3 months of study entry.&#xD;
&#xD;
          7. Patients with low/absent perfusion in the area at or below the gastrocnemius muscle&#xD;
&#xD;
          8. Objective evidence of severe peripheral arterial disease will include an ankle&#xD;
             brachial index (ABI) of less than 0.55, and/or a resting toe brachial index (TBI) of&#xD;
             less than 40.&#xD;
&#xD;
          9. Patients must be competent to give consent.&#xD;
&#xD;
         10. No history of malignant disease except for nonmelanoma skin cancer, no suspicious&#xD;
             findings on chest x-ray, mammography (women over age 35) , Papanicolaou smear (women&#xD;
             over age 40), a normal fecal occult blood (over age 50) and a normal prostate specific&#xD;
             antigen (men over age 45).&#xD;
&#xD;
         11. Patients must have a prothrombin Time (PT) between 12-14 seconds, a partial&#xD;
             thromboplastin time (PTT) of 18-28 seconds, and platelet count &gt;100,000/microliter&#xD;
&#xD;
         12. Patients must have white blood cell count (4.1-10.9x10(3) cells/ÂµL)&#xD;
&#xD;
         13. Normal liver function tests (AST 8 - 20 U/L, ALT 8 - 20 U/L, and total bilirubin 0.1 -&#xD;
             1.0 mg/dL)&#xD;
&#xD;
         14. Patients must be male or post menopausal women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with evidence of active proliferative retinopathy.&#xD;
&#xD;
          2. Patients with poorly controlled diabetes mellitus (HbA1C &gt; 8.5%).&#xD;
&#xD;
          3. Patients with renal insufficiency (Creatinine &gt; 2.5) or failure.&#xD;
&#xD;
          4. Infection as evidenced by WBC count of &gt;15,000 k/cumm and/or temperature &gt;38C.&#xD;
&#xD;
          5. Cellulitis in the afflicted limb that in the opinion of the investigators would&#xD;
             require the use of antibiotics or evidence of osteomyelitis corroborated by&#xD;
             radiographic or scintigraphic examination.&#xD;
&#xD;
          6. Pregnant women (women capable of childbearing must have a negative pregnancy test)&#xD;
&#xD;
          7. Cognitively impaired adult&#xD;
&#xD;
          8. Lower extremity venous disease with pitting edema.&#xD;
&#xD;
          9. History of organ transplant.&#xD;
&#xD;
         10. Patients with ulcer exudates, dry gangrene or exposed bone.&#xD;
&#xD;
         11. Allergies to beta-lactam antibiotics, amphotericin B, or streptomycin&#xD;
&#xD;
         12. Cardiovascular conditions:&#xD;
&#xD;
               -  Exercise limiting angina (Canadian Cardiovascular Society Class &gt; 3&#xD;
&#xD;
               -  Congestive heart failure (New York Heart Association class &gt; 3&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Acute ST elevation myocardial infarction (MI) within 1month&#xD;
&#xD;
               -  Transient ischemic attack or stroke within 1 month&#xD;
&#xD;
               -  Severe valvular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael P Murphy, MD</last_name>
    <phone>317-630-8288</phone>
    <email>mipmurph@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janet Klein, RN</last_name>
    <phone>(317) 962-0287</phone>
    <email>jswklein@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael P Murphy, MD</last_name>
      <phone>317-630-8288</phone>
      <email>mipmurph@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Michael P Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf</url>
    <description>Murphy et al. Allogeneic endometrial regenerative cells: An &quot;Off the shelf solution&quot; for critical limb ischemia? J Transl Med. 2008 Aug 19;6:45.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>March 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <last_update_submitted>March 18, 2012</last_update_submitted>
  <last_update_submitted_qc>March 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>critical limb ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

